| Name | Title | Contact Details |
|---|---|---|
Devin Smith |
General Counsel and Chief Compliance Officer | Profile |
We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant to the target disease. Through our next-generation AAV platform combined with cargo development and state-of-the-art manufacturing, we are tackling monogenetic and sporadic CNS and non-CNS disorders that have previously been challenging to address.
Cannalysis was founded in 2015, in Costa Mesa CA. Initially, Cannalysis exclusively served Southern California with a limited amount of analyses available. As the operational and testing requirements expanded, Cannalysis moved its headquarters to a 12,000 sqft state-of-the-art facility in Santa Ana, CA.
Aker BioMarine is a Norwegian fishing and biotech company providing krill products through a fully documented and secured catch and process chain.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.
Dharmacon Research is a Lafayette, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.